期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

松弛素在心力衰竭患者中临床应用价值 被引量：3

原文传递
导出
摘要 心力衰竭（简称心衰）是21世纪危害人类健康的重要心血管疾病之一,随着心衰人群日益庞大,对心衰的管理也面临非常严峻的挑战.在过去20年,对心衰管理有了较大进展.但心衰患者预后仍很差,大多数治疗不令人满意.此外,超过90％的急性心衰患者都伴有呼吸困难,而且其中的大部分患者是因为呼吸困难来就诊.因此,改善呼吸困难是心衰治疗中一个重要而又与临床紧密相关的靶目标.机体内的松弛素（Relaxin）主要来源于衰竭的心脏,与心衰密切相关.
作者 郑刚
机构地区 天津市第三医院心内科天津市老年病研究所
出处 《中华临床医师杂志（电子版）》 CAS 2013年第11期32-34,共3页 Chinese Journal of Clinicians(Electronic Edition)
关键词 心力衰竭患者 临床应用价值 松弛素 心衰患者 呼吸困难 心血管疾病 人类健康 机体内
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1Xu Q,Lekgabe ED,Gao XM,et al.Endogenous relaxin doesnot affect chronic pressure overload-induced cardiac hyper-trophy and fibrosis[].The Journal of Endocrinology.2008
  • 2Fisher C,Berry C,Blue L,et al.N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure[].Heart.2003
  • 3Xiao-Jun Du,Qi Xu,Edna Lekgabe,Xiao-Ming Gao,Helen Kiriazis,Xiao-Lei Moore,Anthony M Dart,Geoffrey W Tregear,Ross A D Bathgate,Chrishan S Samuel.Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin Experimental Findings:[].Annals of the New York Academy of Sciences.2009
  • 4Kirk P. Conrad,Sanjeev G. Shroff.Effects of Relaxin on Arterial Dilation, Remodeling, and Mechanical Properties[].CURRENT HYPERTENSION REPORTS.2011
  • 5Dschietzig T,Richter C,Bartsch C,Laule M,Armbruster F P,Baumann G,Stangl K.The pregnancy hormone relaxin is a player in human heart failure[].The FASEB journal : official publication of the Federation of American Societies for Experimental Biology.2001
  • 6Hossain Mohammed Akhter,Rosengren K Johan,Samuel Chrishan S,Shabanpoor Fazel,Chan Linda J,Bathgate Ross A D,Wade John D.The minimal active structure of human relaxin-2[].Journal of Biological Chemistry.2011
  • 7M Heringlake,T Kox,J Poeling,S Klaus,T Hanke,N Franz,F Eberhardt,H Heinze,FP Armbruster,L Bahlmann.The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease[].European Journal of Medical Research.2009
  • 8XJ Du,RA Bathgate,CS Samuel,AM Dart,RJ Summers.Cardiovascular effects of relaxin: from basic science to clinical therapy[].Nature reviews Cardiology.2010
  • 9Thomas Dschietzig,Sam Teichman,Elaine Unemori,Susy Wood,Julia Boehmer,Christoph Richter,Gert Baumann,Karl Stangl.First Clinical Experience with Intravenous Recombinant Human Relaxin in Compensated Heart Failure[].Annals of the New York Academy of Sciences.2009
  • 10Pawel Matusik,Marzena Dubiel,Barbara Wizner.Age-related gap in the management of heart failure patients. The National Project of Prevention and Treatment of Cardiovascular Diseases - POLKARD[].CARDIOLOGY JOURNAL.2012

同被引文献37

  • 1蒋正英,覃数.心肌细胞外基质重塑与充血性心力衰竭[J].心血管病学进展,2006,27(2):185-187. 被引量：3
  • 2Chen J, Dharmarajan K, Wang Y, et al. National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol, 2013,61 : 1078-1088.
  • 3Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Meal,2012,10:7.
  • 4Loncar G, yon Haehling S, Tahirovic E, et al. Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: re- sults from the CIBIS-ELD trial.Clin Biochem, 2012,45 : 117-122.
  • 5Sahu BS, Mohan J, Sahu G, et al. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neu- ronal nicotinic aeetylcholine receptor. J Cell Sci,2012,125 (Pt.
  • 6Matusik P, Dubiel M, Wizner B,et al. Age-related gap in the management of heart failure patients. The National Project of Pre- vention and Treatment of Cardiovascular Diseases-POLKARD. Cardiol J,2012,19:146-152.
  • 7Hossain MA, Rosengren K J, Samuel CS, et al. The minimal ac- tive structure of human relaxin-2. J Biol Chem,2011,286: 34555-34565.
  • 8Teerlink JR, Cotter G, Davison BA,et al. For the RELAXIn in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, re- combinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomlsed, placebo-controlled trial. Lancet, 2013,381(9860) :29-39.
  • 9Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on inter-pretation of test results. Am Heart J,2013,165:995-999.
  • 10Erkilet G, Ozpeker C, BOthig D,et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant,2013,32: 221-230.

引证文献3

二级引证文献13

中华临床医师杂志（电子版）
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部